Clinical Trials Directory

Trials / Completed

CompletedNCT04388397

Immediate-access Arteriovenous Versus Standard Arteriovenous Grafts in Hemodialysis Patients

Immediate-access Arteriovenous Versus Standard Arteriovenous Grafts in Hemodialysis Patients: A Randomized Clinical Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
477 (actual)
Sponsor
Egyptian Biomedical Research Network · Network
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.

Detailed description

The study aimed to evaluate and compare patency rate and complications of standard arteriovenous grafts (SAVGs) and immediate-access arteriovenous grafts (IAAVGs) in end stage renal disease (ESRD) patients for one year after the intervention. Patients were randomly divided into two groups: SAVGs group and IAAVGs group. Patients with ESRD with no chance for native AVF were examined clinically and by duplex ultrasonography preoperatively. Follow up was for one year. Primary end points were the success rate, complications rate (hematoma, pseudo-aneurysm, graft site infection, systemic bacteremia), time of first cannulation. Secondary end points were primary and secondary patency within one year.

Conditions

Interventions

TypeNameDescription
PROCEDUREArteriovenous GraftsArteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.

Timeline

Start date
2017-08-15
Primary completion
2020-04-10
Completion
2020-04-10
First posted
2020-05-14
Last updated
2020-07-23

Locations

2 sites across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04388397. Inclusion in this directory is not an endorsement.